Inhibition of hepatitis B virus replication in cultured cells and in vivo using 2′-O-guanidinopropyl modified siRNAs
- 1 October 2013
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 21 (20) , 6145-6155
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Progress Toward In Vivo Use of siRNAs-IIMolecular Therapy, 2012
- A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effectsNucleic Acids Research, 2010
- Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttlesNucleic Acids Research, 2009
- A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicityNucleic Acids Research, 2009
- Biogenesis of small RNAs in animalsNature Reviews Molecular Cell Biology, 2009
- MicroRNAs in Disease and Potential Therapeutic ApplicationsMolecular Therapy, 2007
- Specific Inhibition of HBV Replication In Vitro and In Vivo With Expressed Long Hairpin RNAMolecular Therapy, 2007
- RNAi therapeutics: Principles, prospects and challengesAdvanced Drug Delivery Reviews, 2007
- Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarityRNA, 2006
- Argonaute2 Is the Catalytic Engine of Mammalian RNAiScience, 2004